Despite the fact that non-alcoholic fatty liver disease (NAFLD) and its severe clinical forms [non-alcoholic steatohepatitis (NASH) and NASH-cirrhosis] are highly prevalent in the general population, there are no licensed drugs for NAFLD, and lifestyle intervention remains the only treatment accepted by international guidelines. This is despite massive investments in research by pharmaceutical companies. In the presence of type 2 diabetes, novel anti-diabetic drugs offer an opportunity to reduce the burden of NAFLD, by adequate control of glucose and lipid metabolism, also reducing the risk of NASH progression, advanced fibrosis, and finally hepatocellular carcinoma. We extensively reviewed the literature, based either on registration studies, ad hoc randomized studies or real-world data, to define the effectiveness of anti-diabetic drugs in the treatment of NAFLD and prevention of hepatocellular carcinoma (HCC). Metformin provides the best evidence for decreased risk of HCC, pioglitazone was associated with decreased progression to fibrosis, glucagon-like peptide-1 receptor agonists offer a possible opportunity to reduce NAFLD progression coupled with a definite protection for cardiovascular outcomes, and sodium-glucose cotransporter-2 inhibitors are likely to reduce lipid burden, simultaneously reducing the risk of progressive renal and heart failure. For the latter two drug classes, the effects on NAFLD might largely explained by decreased body weight, in keeping with the beneficial effects of intensive lifestyle intervention.

Brodosi, L., Musio, A., Barbanti, F.A., Mita, D., Marchesini, G., Petroni, M.L. (2020). Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential. HEPATOMA RESEARCH, 2020, 82-92 [10.20517/2394-5079.2020.88].

Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential

Brodosi, Lucia
Primo
Writing – Original Draft Preparation
;
Musio, Alessandra
Secondo
Writing – Review & Editing
;
Barbanti, Francesca Alessandra
Supervision
;
Mita, Dorina
Supervision
;
Marchesini, Giulio
Writing – Review & Editing
;
Petroni, Maria Letizia
Ultimo
Supervision
2020

Abstract

Despite the fact that non-alcoholic fatty liver disease (NAFLD) and its severe clinical forms [non-alcoholic steatohepatitis (NASH) and NASH-cirrhosis] are highly prevalent in the general population, there are no licensed drugs for NAFLD, and lifestyle intervention remains the only treatment accepted by international guidelines. This is despite massive investments in research by pharmaceutical companies. In the presence of type 2 diabetes, novel anti-diabetic drugs offer an opportunity to reduce the burden of NAFLD, by adequate control of glucose and lipid metabolism, also reducing the risk of NASH progression, advanced fibrosis, and finally hepatocellular carcinoma. We extensively reviewed the literature, based either on registration studies, ad hoc randomized studies or real-world data, to define the effectiveness of anti-diabetic drugs in the treatment of NAFLD and prevention of hepatocellular carcinoma (HCC). Metformin provides the best evidence for decreased risk of HCC, pioglitazone was associated with decreased progression to fibrosis, glucagon-like peptide-1 receptor agonists offer a possible opportunity to reduce NAFLD progression coupled with a definite protection for cardiovascular outcomes, and sodium-glucose cotransporter-2 inhibitors are likely to reduce lipid burden, simultaneously reducing the risk of progressive renal and heart failure. For the latter two drug classes, the effects on NAFLD might largely explained by decreased body weight, in keeping with the beneficial effects of intensive lifestyle intervention.
2020
Brodosi, L., Musio, A., Barbanti, F.A., Mita, D., Marchesini, G., Petroni, M.L. (2020). Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential. HEPATOMA RESEARCH, 2020, 82-92 [10.20517/2394-5079.2020.88].
Brodosi, Lucia; Musio, Alessandra; Barbanti, Francesca Alessandra; Mita, Dorina; Marchesini, Giulio; Petroni, Maria Letizia
File in questo prodotto:
File Dimensione Formato  
3791.pdf

accesso aperto

Descrizione: Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential
Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 495.4 kB
Formato Adobe PDF
495.4 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/796924
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact